rs373249008
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_000465.4(BARD1):c.562C>T(p.Pro188Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,459,722 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000465.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000401 AC: 1AN: 249196Hom.: 0 AF XY: 0.00000743 AC XY: 1AN XY: 134562
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1459722Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 725806
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces proline with serine at codon 188 of the BARD1 protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer (PMID: 32866190, 33646313). This variant has been identified in 1/249196 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.P188S variant (also known as c.562C>T), located in coding exon 4 of the BARD1 gene, results from a C to T substitution at nucleotide position 562. The proline at codon 188 is replaced by serine, an amino acid with similar properties. This alteration was detected in an individual with breast cancer diagnosed at age 53 from a cohort of 1018 participants with invasive breast cancer and/or ovarian cancer born in the Caribbean (George SHL et al. JAMA Netw Open, 2021 Mar;4:e210307). This alteration was also detected in a cohort of 97 breast cancer-affected individuals of African and European descent who underwent testing of 14 cancer susceptibility genes (Bishop MR et al. PLoS One, 2020 Aug;15:e0238295). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Familial cancer of breast Uncertain:1
This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 188 of the BARD1 protein (p.Pro188Ser). This variant is present in population databases (rs373249008, gnomAD 0.007%). This missense change has been observed in individual(s) with breast cancer (PMID: 33646313). ClinVar contains an entry for this variant (Variation ID: 232775). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at